This information was originally presented at the NCCN 10^th Annual Congress: Hematologic Malignancies™ held in San Francisco, California.

This information was originally presented at the NCCN 10^th Annual Congress: Hematologic Malignancies™ held in San Francisco, California.

Essential thrombocythemia is well-known to transform to other myeloid disorders, such as leukemia; however, the risk for development of lymphoma is not as well studied.

This information was originally presented on September 20, 2014, at the NCCN 9th Annual Congress: Hematologic Malignancies™ held in New York, New York.

This information was originally presented on September 20, 2014, at the NCCN 9th Annual Congress: Hematologic Malignancies™ held in New York, New York.

This information was originally presented on September 20, 2014, at the NCCN 9th Annual Congress: Hematologic Malignancies™ held in New York, New York.

This information was originally presented on September 20, 2014, at the NCCN 9th Annual Congress: Hematologic Malignancies™ held in New York, New York.

The goal of this activity is to improve participants’ competence in implementing the most recent guideline changes and clinical advances in the management of patients with indolent non-Hodgkin’s lymphomas.

The goal of this activity is to improve participants’ competence in implementing the most recent guideline changes and clinical advances in the management of patients with indolent non-Hodgkin’s lymphomas.

The goal of this activity is to improve participants’ competence in implementing the most recent guideline changes and clinical advances in the management of patients with indolent non-Hodgkin’s lymphomas.